Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

Historically, tobacco plants are responsible for their share of illness and death. Now they may help control the COVID-19 pandemic.

Two biotech companies are using the tobacco plant, Nicotiana benthamiana, as bio-factories to produce a key protein from the coronavirus that can be used in a vaccine.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Companies trying to make a vaccine for COVID-19 are trying a variety of approaches. Most involve laboratories capable of sophisticated biotechnology, but NPR's Joe Palca has this report about one approach for creating a vaccine which starts in a greenhouse.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

All right, now let's work through what treatments the president is getting and what they tell us with NPR science correspondent Joe Palca. Good morning, Joe.

JOE PALCA, BYLINE: Good morning.

White House physician Sean Conley says that President Trump was doing "very well" and that the symptoms he had are resolving and improving.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Scientists and engineers in California are building a unique camera for a unique telescope.

The Rubin Observatory telescope going up on Cerro Pachón in north-central Chile can capture an unusually large swath of sky in a single image.

The camera capable of capturing those images has to be enormous. The one researchers are building at the SLAC National Accelerator Laboratory in Menlo Park, Calif., certainly is.

Under normal circumstances, it could take years — if not decades — to bring a new vaccine to market. The COVID-19 pandemic has changed all that. In May, the Trump administration launched Operation Warp Speed with the goal of delivering initial doses of a safe and effective vaccine by January 2021 — shortening the development time from years to months.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Turns out that cows may be helpful to us in the pandemic. There's a biotech company in South Dakota using cows to make antibodies for treating human disease. And lately, they've been making antibodies for COVID-19. Here's NPR's Joe Palca.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

The global race for a coronavirus vaccine is on. And around the world, hopes for a vaccine are high.

(SOUNDBITE OF MONTAGE)

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

In an unusual move, the Food and Drug Administration today announced that is making it easier for doctors to try an experimental treatment for COVID-19 patients that uses plasma from people who had the disease and recovered.

There is scant evidence it works in people infected with the coronavirus, but the approach has been tried for other illnesses.

The federal government is now adding supercomputers to its tool set in the hunt for ways to stop COVID-19.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

The Year In Science News

Dec 26, 2019

NOEL KING, HOST:

All right, astronomers have known about black holes for a long time, but they never had a picture of one until this year. We asked NPR science correspondent Joe Palca what were the three biggest science stories of the year, and here's what he said.

It's hard for doctors to do a thorough eye exam on infants. They tend to wiggle around — the babies, that is, not the doctors.

But a new smartphone app takes advantage of parents' fondness for snapping pictures of their children to look for signs that a child might be developing a serious eye disease.

The app is the culmination of one father's five-year quest to find a way to catch the earliest signs of eye disease, and prevent devastating loss of vision.

Copyright 2019 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Copyright 2019 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Many medical tests require blood drawn with a needle. But as NPR's Joe Palca reports, some engineers in California have turned to another bodily fluid for doing these tests - sweat.

STEVE INSKEEP, HOST:

A telescope now under construction promises to revolutionize astronomy. It's being built atop a mountain in Chile, in the Andes. It's called the LSST. It is a survey telescope taking wide-angle views of the sky. And this telescope is expected to spot rare events that previously have been hard or impossible to find. NPR science correspondent Joe Palca toured the telescope's construction site.

MICHEL MARTIN, HOST:

Much of South America experienced a solar eclipse this week. NPR's Joe Palca went to Chile to see it in its totality. And because half of the world's major telescopes are in Chile, he decided to stick around and see what researchers are studying. And Joe Palca is with us now from 17,000 feet.

Hi, Joe.

JOE PALCA, BYLINE: Hey, Michel. How are you doing?

MARTIN: OK. So where are you right now, exactly?

Copyright 2018 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

ARI SHAPIRO, HOST:

A giant dust storm on Mars is threatening to end the mission of a NASA rover. The rover called Opportunity depends on solar panels to charge its batteries. Right now, the storm has practically blotted out the sun. NPR's Joe Palca has more.

JOE PALCA, BYLINE: On May 30, NASA's Mars Reconnaissance Orbiter spotted a dust storm - a storm that was heading toward Opportunity's location near the equator. Over the next few days, the storm intensified. And by last Sunday, the power from Opportunity's solar panels had dropped to a trickle.

For the first time, scientists say they have clear evidence that the chemical building blocks of life exist on Mars.

What they can't say yet is whether there is, or ever was, life on the Red Planet.

Pages